Study testing new drug combinations for advanced cancers
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (16 or older for one rare cancer group).
- You must be generally active and able to care for yourself (ECOG performance status 0 or 1).
- Your cancer must be one of the specific types listed in the study, such as pancreatic, colorectal, lung, stomach, esophageal, head and neck, bile duct, or a rare soft tissue cancer.
- You must have had at least one prior treatment for advanced disease, or for some groups, no prior treatment is okay.
- You must have adequate liver, kidney, and blood cell counts.
- You must not have certain heart conditions, active infections, autoimmune diseases, or untreated brain metastases.
- You must agree to use effective birth control if applicable.
- You cannot have received certain cancer treatments or live vaccines within a specified time before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.